In response to a request from the Centres for Disease Control and Prevention, US authorities have approved peramivir as an emergency treatment for patients with special cases of the 2009 H1N1 influenza infection.

Peramivir, manufactured by BioCryst Pharmaceuticals, will be made as an intravenous solution for adults and children who do not respond to oral or inhaled therapies or when intravenous administration is seen as the only feasible option.

The decision by the US Food and Drug Administration makes peramivir the first intravenously administered antiviral to be approved for the treatment of influenza.

The declaration of emergency use was approved after a review of all available scientific data, during which peramivir met the required targets.